Emerging utility of once-weekly exenatide in patients with type 2 diabetes

References

• 2014 Statistics Report Data and Statistics Diabetes CDC2014 Available from: http://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.htmlAccessed December 31, 2014
   Google Scholar
• Centers for Disease Control and Prevention About NCHSNCHS Fact Sheets – NCHS Data on Obesity2014 [updated June 4, 2014]. Available from: http://www.cdc.gov/nchs/data/factsheets/factsheet_obesity.htmAccessed October 5, 2015
   Google Scholar
• DruckerDJEnhancing incretin action for the treatment of type 2 diabetesDiabetes Care200326102929 294014514604
   PubMed Web of Science ®Google Scholar
• FurmanBLThe development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agentToxicon2012594464 47121194543
   PubMed Web of Science ®Google Scholar
• SeewoodharyJGriffinLBainSCCritical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitusDiabetes Metab Syndr Obes20103165 17221437086
   PubMedGoogle Scholar
• DeYoungMBMacConellLSarinVTrautmannMHerbertPEncapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetesDiabetes Technol Ther201113111145 115421751887
   PubMed Web of Science ®Google Scholar
• FinemanMFlanaganSTaylorKPharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingClin Pharmacokinet201150165 7421142268
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2015: summary of revisionsDiabetes Care201438Suppl_1S4 S4
   Google Scholar
• DiamantMVan GaalLStranksSOnce weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trialLancet201037597332234 224320609969
   PubMed Web of Science ®Google Scholar
• KimDMacConellLZhuangDEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care20073061487 149317353504
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKDURATION-1 Study GroupExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240 125018782641
   PubMed Web of Science ®Google Scholar
• BlevinsTPullmanJMalloyJDURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetesJ Clin Endocrinol Metab20119651301 131021307137
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacconellLDURATION-2 Study GroupEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet20103769739431 43920580422
   PubMed Web of Science ®Google Scholar
• Russell-JonesDCuddihyRMHanefeldMDURATION-4 Study GroupEfficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDiabetes Care2012352252 25822210563
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLGuerciBExenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialLancet Diabetes Endocrinol201426464 47324731672
   PubMed Web of Science ®Google Scholar
• TaylorKGurneyKHanJPencekRWalshBTrautmannMExenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 yearsBMC Endocr Disord201111921529363
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLStranksSSafety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeksDiabetes Care2012354683 68922357185
   PubMed Web of Science ®Google Scholar
• ChiquetteETothPPRamirezGCobbleMChiltonRTreatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markersVasc Health Risk Manag20128621 62923166441
   PubMedGoogle Scholar
• BergenstalRMLiYPorterTKBWeaverCHanJExenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c <7%, without weight gain or hypoglycaemia, over 52 weeksDiabetes Obes Metab2013153264 27123078638
   PubMed Web of Science ®Google Scholar
• RobinsonLEHoltTAReesKRandevaHSO’HareJPEffects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open201331e001986
   PubMed Web of Science ®Google Scholar
• KatoutMZhuHRutskyJEffect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regressionAm J Hypertens2013271130 13924263424
   PubMed Web of Science ®Google Scholar
• GrimmMHanJWeaverCEfficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trialsPostgrad Med2013125347 5723748506
   PubMed Web of Science ®Google Scholar
• PottsJEGrayLJBradyEMKhuntiKDaviesMJBodicoatDHThe effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysisPLoS One2015106e012676926121478
   PubMed Web of Science ®Google Scholar
• YooBKTrillerDMYooDJExenatide: a new option for the treatment of type 2 diabetesAnn Pharmacother200640101777 178416985091
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialClin Ther200729112333 234818158075
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2014381140 14925538310
   PubMed Web of Science ®Google Scholar
• TuttleKRHeilmannCHoogwerfBJBrownCAndersonPWEffects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetesAm J Kidney Dis2013622396 39823684754
   PubMed Web of Science ®Google Scholar
• VijanSSussmanJBYudkinJSHaywardRAEffect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitusJAMA Intern Med201417481227 123424979148
   PubMed Web of Science ®Google Scholar
• SinhaARajanMHoergerTPogachLCosts and consequences associated with newer medications for glycemic control in type 2 diabetesDiabetes Care2010334695 70020056950
   PubMed Web of Science ®Google Scholar
• BestJHRubinRRPeyrotMWeight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatmentDiabetes Care2011342314 31921270189
   PubMed Web of Science ®Google Scholar
• ClarkePGrayAHolmanREstimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)Med Decis Making2002224340 34912150599
   PubMed Web of Science ®Google Scholar
• MatzaLSBoyeKSYurginNValidation of two generic patient-reported outcome measures in patients with type 2 diabetesHealth Qual Life Outcomes200754717672906
   PubMed Web of Science ®Google Scholar
• CharpentierGFleuryFDubrocaIVaurLClersonPElectronic pill-boxes in the evaluation of oral hypoglycemic agent complianceDiabetes Metab2005312189 19515959425
   PubMed Web of Science ®Google Scholar
• PollackMFPurayidathilFWBolgeSCWilliamsSAPatient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of lifeDiabetes Res Clin Pract2010872204 21020036433
   PubMed Web of Science ®Google Scholar